Michael L. Levitz - 11 Mar 2022 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
EVP, CFO, Treasurer
Signature
/s/ Michael L. Levitz
Issuer symbol
ANIK
Transactions as of
11 Mar 2022
Net transactions value
$0
Form type
4
Filing time
15 Mar 2022, 17:01:01 UTC
Previous filing
11 Mar 2022
Next filing
11 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Award $0 +26,664 $0.000000 26,664 11 Mar 2022 Common Stock 26,664 $0.000000 Direct F1
transaction ANIK Stock Option (Right to Buy) Award $0 +38,979 $0.000000 38,979 11 Mar 2022 Common Stock 38,979 $28.14 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023.
F2 Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
F3 The premium priced stock options vest in three equal annual installments beginning on March 11, 2023.